Publications by authors named "Oleksandr Sydorenko"
Article Synopsis
- The MONET1 phase 3 study assessed the effectiveness of motesanib combined with carboplatin/paclitaxel versus a placebo with the same chemotherapy for first-line treatment of advanced squamous non-small-cell lung cancer (NSCLC).
- Enrollment of patients with squamous histology was stopped due to increased early mortality and bleeding issues, while nonsquamous enrollment was temporarily paused and later resumed after protocol changes.
- The results showed that motesanib addition led to higher rates of serious adverse events compared to the placebo, with similar overall survival rates of approximately 11.1 months for the motesanib group and 10.7 months for the placebo group, indicating unacceptable toxicity.
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
Giorgio V Scagliotti Ihor Vynnychenko Keunchil Park Yukito Ichinose Kaoru Kubota Oleksandr Sydorenko
J Clin Oncol
August 2012
Article Synopsis
- A study investigated if motesanib, an oral medication, combined with chemotherapy (carboplatin/paclitaxel) could enhance overall survival (OS) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC), especially those with adenocarcinoma.
- The results showed that while the median OS was slightly higher with motesanib (13.0 months) compared to placebo (11.0 months), the difference was not statistically significant, with a hazard ratio of 0.90 (P = .14).
- Additionally, motesanib treatment led to more adverse events, including higher instances of severe side effects, but did show improved progression-free survival (PFS) and objective response rate